alovudine has been researched along with Neoplasms in 63 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 27 (42.86) | 29.6817 |
| 2010's | 36 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aboagye, EO; Boellaard, R; Cysouw, MCF; De Langen, AJ; Frings, V; Hoekstra, OS; Kenny, LM; Kobe, C; Kramer, GM; Wolf, J; Wondergem, MJ | 1 |
| Jung, KH; Kang, KJ; Kim, JY; Kim, KM; Kim, MH; Ko, IO; Lee, KC; Lee, YJ; Lim, SM; Noh, I; Park, JA | 1 |
| Aboagye, EO; Asselin, MC; Boellaard, R; de Langen, AJ; Hoekstra, OS; Jackson, A; Jansma, EP; Kenny, L; Kramer, GM; Liu, Y; Trigonis, I | 1 |
| Binger, K; Bruce, JY; Carmichael, L; Dukart, G; Eickhoff, J; Harrow, K; Heideman, J; Jeraj, R; Kolesar, J; Liang, C; Liu, G; Perlman, S; Rampurwala, M; Scarpelli, M | 1 |
| Babur, M; Brown, G; Burrows, N; Cawthorne, C; Dive, C; Forster, D; Gieling, RG; Gregory, J; Hiscock, D; Hodgkinson, C; McMahon, A; Morrow, CJ; Radigois, M; Simpson, K; Smigova, A; Williams, KJ; Wilson, I | 1 |
| Ayers, GD; Coffey, RJ; Manning, HC; McKinley, ET; Saleh, SA; Smith, RA; Washington, MK; Zhao, P | 1 |
| Jeraj, R; Perlman, SB; Vanderhoek, M | 1 |
| Benz, MR; Buck, AK; Herrmann, K; Pomykala, KL; Wieder, HA | 1 |
| Buck, AK; Herrmann, K | 1 |
| Chalkidou, A; Fenwick, JD; Landau, DB; Liu, D; Marsden, PK | 1 |
| Armstrong, JO; Fink, JR; Friesen, A; Krohn, KA; Link, JM; Muzi, M; Peck, M; Pollack, HA; Shankland, EG; Shoner, SC | 1 |
| Kiyono, Y; Kume, K; Lin, C; Martinez, ME; Mori, T; Okazawa, H | 1 |
| Bezak, E; Jennings, M; Marcu, LG | 1 |
| Bruce, JY; Carmichael, LL; Eickhoff, JC; Heideman, JL; Jeraj, R; Kolesar, JM; Liu, G; Perlman, SB; Scully, PC | 1 |
| Bollineni, VR; Jansma, EP; Kramer, GM; Liu, Y; Oyen, WJ | 1 |
| Collins, JM; Douglas, KA; Jones, SK; Lawhorn-Crews, JM; Mangner, TJ; McHugh, CI; Modi, D; Shields, AF | 1 |
| Bruce, JY; Carmichael, L; Eickhoff, J; Jeraj, R; Kolesar, J; Liu, G; Perlman, S; Scarpelli, M | 1 |
| Aboagye, EO; Bollineni, VR; Heinzmann, K; Jacobs, AH; Kramer, GM; Liu, Y; Schelhaas, S; Shields, AF; Soloviev, D; Waterton, JC | 1 |
| Bading, JR; Shields, AF | 1 |
| Buck, AK; Dechow, T; Herrmann, K; Schwaiger, M; Shen, C; Wester, HJ | 1 |
| Han, DL; Jiang, WR; Yu, JM | 1 |
| Ahn, SH; Cheon, GJ; Choi, CW; Chun, KS; Kang, JH; Lee, TS; Lim, SM; Moon, BS | 1 |
| Avril, N; Barwick, T; Bencherif, B; Mountz, JM | 1 |
| Jackson, A; Trigonis, I | 1 |
| Atuegwu, NC; Gore, JC; Yankeelov, TE | 1 |
| Ametamey, SM; André, PA; Bischof Delaloye, A; Buchegger, F; Dupertuis, YM; Gruetter, R; Kosinski, M; Lanz, B; Lehr, HA; Mlynarik, V; Perillo-Adamer, F; Poitry-Yamate, C; Ross, TL; Viertl, D | 1 |
| Cass, CE; Gati, WP; Graham, K; Jans, HS; McEwan, A; McQuarrie, S; Mercer, J; Paproski, RJ; Wuest, M; Young, JD | 1 |
| Emerick, LE; Krohn, KA; Plotnik, DA; Schwartz, JL; Unadkat, JD | 1 |
| Brepoels, L; De Saint-Hubert, M; Mottaghy, FM | 1 |
| Benezra, R; Blasberg, RG; Escorcia, FE; Henke, E; McDevitt, MR; Scheinberg, DA; Smith-Jones, P; Villa, CH | 1 |
| Guleryuz, S; Manning, HC; Smith, RA | 1 |
| Chung, JH; Kang, HY; Kang, JS; Kim, HM; Kim, MH; Kim, SB; Kim, SY; Lee, SJ; Moon, DH; Oh, SJ; Park, SK; Ryu, JS | 1 |
| Conti, P; Graham, M; Hoffman, J | 1 |
| Bolen, JB; Chakravarty, A; Chen, W; Claiborne, CF; Ecsedy, JA; Germanos, MS; Gershman, RE; Hoar, KM; Huck, JJ; Hyer, ML; Janowick, DA; Leroy, PJ; Manfredi, MG; Sells, TB; Shinde, V; Silva, MD; Silverman, L; Stroud, SG; Wysong, DR; Zhang, M | 1 |
| Carmichael, L; Chao, B; Eickhoff, J; Harrison, M; Ivy, P; Jeraj, R; Kolesar, J; Liu, G; Marnocha, R; Perlman, S; Simoncic, U; Vanderhoek, M; Wilding, G | 1 |
| Affolter, T; Buckman, D; Christensen, JG; Cullinane, C; Fahey, NR; Kuszpit, K; Lappin, PB; Li, W; Lira, ME; Nichols, T; O'Brien, P; Painter, CL; Spilker, M; Wong, A; Yan, Z; Zasadny, K; Zhang, CC; Zhang, Q | 1 |
| Aboagye, E; Honess, D; Lewis, D; Soloviev, D | 1 |
| Shields, AF | 2 |
| Aboagye, E; Kimberley, S; Rosso, L; Tomasi, G; Turkheimer, F | 1 |
| Chalkidou, A; Cornelius, VR; Landau, DB; Marsden, PK; O'Doherty, MJ; Odell, EW | 1 |
| Flamen, P; Garcia, C; Gebhart, G | 1 |
| Aboagye, EO; Barthel, H; Brady, F; Cleij, MC; Collingridge, DR; He, Q; Hutchinson, OC; Luthra, SK; Osman, S; Price, PM | 1 |
| Grierson, JR; Jordan, R; Krohn, KA; Schwartz, JL; Tamura, Y | 1 |
| Cobben, DC; Elsinga, PH; Jager, PL; van Waarde, A | 1 |
| Aboagye, EO; Kenny, LM; Price, PM | 1 |
| Chatal, JF; Couturier, O; Hustinx, R | 1 |
| Been, LB; Cobben, DC; Elsinga, PH; Hoekstra, HJ; Jager, PL; Suurmeijer, AJ | 1 |
| Grierson, JR; Krohn, KA; Mankoff, DA; Muzi, M; Vesselle, H; Wells, JM | 1 |
| Briston, DA; Chandupatla, S; Collins, JM; Douglas, KA; Heilbrun, LK; Lawhorn-Crews, J; Mangner, TJ; Muzik, O; Shields, AF | 1 |
| Carrió, I; Ell, PJ; Pakzad, F | 1 |
| Campone, M; Carlier, T; Chatal, JF; Couturier, O; Hustinx, R; Leost, F | 1 |
| de Korte, MA; de Vries, EG; Jager, PL; Koopmans, KP; Lub-de Hooge, MN; Perik, PJ; van Waarde, A | 1 |
| Deisenhofer, S; Reske, SN | 1 |
| Charnley, N; Price, P; Saleem, A | 1 |
| Chi, DY; Kil, HS; Kim, EN; Lee, SJ; Moon, DH; Oh, SJ; Ryu, JS | 1 |
| Kumar, R | 1 |
| Brockenbrough, JS; Grierson, JR; Jordan, R; Rasey, JS; Schwartz, JL; Vesselle, H; Wiens, LW | 1 |
| Ell, PJ; Groves, AM; Haim, SB; Win, T | 1 |
| Vallabhajosula, S | 1 |
| Grierson, J; Salskov, A; Tammisetti, VS; Vesselle, H | 1 |
| Dimitrakopoulou-Strauss, A; Strauss, LG | 1 |
| Eisenhut, M; Haberkorn, U; Mier, W | 1 |
25 review(s) available for alovudine and Neoplasms
| Article | Year |
|---|---|
Repeatability of quantitative
Topics: Dideoxynucleosides; Humans; Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Reproducibility of Results | 2018 |
PET tracers in musculoskeletal disease beyond FDG.
Topics: Amino Acids; Bone Diseases; Bone Neoplasms; Carbon Radioisotopes; Choline; Dideoxynucleosides; Fluorine Radioisotopes; Humans; Musculoskeletal Diseases; Neoplasms; Positron-Emission Tomography | 2014 |
Proliferation imaging with ¹⁸F-fluorothymidine PET/computed tomography: physiologic uptake, variants, and pitfalls.
Topics: Abdomen; Aging; Dideoxynucleosides; Fluorine Radioisotopes; Head; Humans; Neck; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Thorax; Time Factors; Tissue Distribution; Tomography, X-Ray Computed; Urogenital System | 2014 |
Applications of PET imaging with the proliferation marker [18F]-FLT.
Topics: Cell Proliferation; Dideoxynucleosides; Humans; Molecular Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Thymidine Kinase | 2015 |
PET-specific parameters and radiotracers in theoretical tumour modelling.
Topics: Cell Proliferation; Coordination Complexes; Dideoxynucleosides; Diffusion; Fluorodeoxyglucose F18; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glucose; Humans; Hydrogen-Ion Concentration; Hypoxia; Misonidazole; Models, Theoretical; Multimodal Imaging; Neoplasms; Neovascularization, Pathologic; Organometallic Compounds; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Thiosemicarbazones; Tomography, X-Ray Computed | 2015 |
A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients.
Topics: Cell Proliferation; Dideoxynucleosides; Disease-Free Survival; Humans; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Treatment Outcome | 2016 |
Preclinical Applications of 3'-Deoxy-3'-[
Topics: Animals; Dideoxynucleosides; Drug Evaluation, Preclinical; Drug Monitoring; Neoplasms; Positron Emission Tomography Computed Tomography | 2017 |
Imaging of cell proliferation: status and prospects.
Topics: Animals; Cell Proliferation; Dideoxynucleosides; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
[Application and future prospect of 18F-FLT PET-CT in guiding delineation of biological target volume].
Topics: Dideoxynucleosides; False Positive Reactions; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Inflammation; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiotherapy, Intensity-Modulated; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation.
Topics: Brain Neoplasms; Cell Proliferation; Dideoxynucleosides; Drug Evaluation, Preclinical; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Imaging pharmacodynamics in oncology: the potential significance of "flares".
Topics: Animals; Biological Transport; Diagnostic Imaging; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Neoplasms; Pharmacokinetics; Radioactive Tracers | 2010 |
Molecular imaging metrics to evaluate response to preclinical therapeutic regimens.
Topics: Diagnostic Imaging; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Molecular Imaging; Neoplasms; Neovascularization, Pathologic; Positron-Emission Tomography; Thymidine Kinase | 2011 |
[(18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment.
Topics: Biomarkers, Pharmacological; Biomarkers, Tumor; Cell Proliferation; Diagnostic Imaging; Dideoxynucleosides; Humans; Neoplasms; Positron-Emission Tomography; Prognosis; Radioactive Tracers; Treatment Outcome | 2012 |
Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis.
Topics: Antigens, Neoplasm; Bias; Biomarkers; Biopsy; Cell Division; Clinical Trials as Topic; Dideoxynucleosides; Female; Fluorine Radioisotopes; Humans; Immunohistochemistry; Ki-67 Antigen; Male; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Research Design; Surveys and Questionnaires; Tissue Distribution | 2012 |
New PET imaging agents in the management of solid cancers.
Topics: Apoptosis; Cell Hypoxia; Cell Membrane; Cell Proliferation; Choline; Dideoxynucleosides; Heterocyclic Compounds, 1-Ring; Humans; Multimodal Imaging; Neoplasms; Peptides, Cyclic; Positron-Emission Tomography; Radiopharmaceuticals; Sodium Fluoride; Somatostatin; Tissue Distribution; Tomography, X-Ray Computed | 2012 |
Positron emission tomography imaging of cell proliferation in oncology.
Topics: Antiviral Agents; Cell Cycle; Cyclins; Dideoxynucleosides; DNA; Humans; Kinetics; Neoplasms; Phenotype; Thymidine; Tomography, Emission-Computed | 2004 |
[Fluorinated analogs of nucleosides and fluorinated tracers of gene expression for positron emission tomography].
Topics: Animals; Antiviral Agents; Dideoxynucleosides; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Ganciclovir; Genes, Reporter; Genetic Therapy; Guanine; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Simplexvirus | 2004 |
[18F]FLT-PET in oncology: current status and opportunities.
Topics: Animals; Dideoxynucleosides; Humans; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Severity of Illness Index | 2004 |
[Is 3'-deoxy-3'- [18F] fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG?].
Topics: Animals; Dideoxynucleosides; Fluorine Radioisotopes; Humans; Neoplasms; Positron-Emission Tomography; Sensitivity and Specificity | 2005 |
Molecular imaging: what can be used today.
Topics: Animals; Biochemical Phenomena; Biomarkers, Tumor; Diagnostic Imaging; Dideoxynucleosides; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Cell Surface | 2005 |
Clinical molecular imaging with positron emission tomography.
Topics: Antineoplastic Agents; Dideoxynucleosides; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2006 |
Non-[18F]FDG PET in clinical oncology.
Topics: Antibodies; Choline; Dideoxynucleosides; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Medical Oncology; Neoplasms; Oxygen; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Estrogen; Receptors, Somatostatin | 2007 |
(18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Topics: Amino Acids; Animals; Bone and Bones; Cell Hypoxia; Choline; Dideoxynucleosides; Dihydroxyphenylalanine; Estradiol; Fluorine Radioisotopes; Fluoroacetates; Fluorodeoxyglucose F18; Glucose; Humans; Membrane Lipids; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |
FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine.
Topics: Cell Proliferation; Dideoxynucleosides; Fluorine Radioisotopes; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2007 |
[18F]FLT; portrait of a proliferation marker.
Topics: Animals; Cell Division; Dideoxynucleosides; Fluorine Radioisotopes; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
4 trial(s) available for alovudine and Neoplasms
| Article | Year |
|---|---|
Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dideoxynucleosides; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Oxindoles; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Vascular Endothelial Growth Factor A | 2018 |
Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography.
Topics: Adult; Aged; Axitinib; Dideoxynucleosides; Disease Progression; Female; Fluorine Radioisotopes; Humans; Imidazoles; Indazoles; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Substance Withdrawal Syndrome; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A | 2015 |
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Dideoxynucleosides; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Indoles; Kidney; Liver Neoplasms; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Neoplasms; Positron-Emission Tomography; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
A simplified analysis of [18F]3'-deoxy-3'-fluorothymidine metabolism and retention.
Topics: Computer Simulation; Dideoxynucleosides; Humans; Metabolic Clearance Rate; Models, Biological; Neoplasms; Radioisotope Dilution Technique; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution | 2005 |
34 other study(ies) available for alovudine and Neoplasms
| Article | Year |
|---|---|
Baseline and longitudinal variability of normal tissue uptake values of [
Topics: Biological Transport; Cell Proliferation; Dideoxynucleosides; Female; Humans; Image Processing, Computer-Assisted; Male; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Tissue Distribution | 2017 |
Preliminary
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Fluorine-19 Magnetic Resonance Imaging; Heterografts; Humans; MCF-7 Cells; Mice; Neoplasms | 2017 |
[18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dideoxynucleosides; Disease Models, Animal; Female; HCT116 Cells; Humans; Indazoles; Mice; Neoplasm Metastasis; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Positron-Emission Tomography; Signal Transduction; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.
Topics: Animals; Biomarkers; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Disease Models, Animal; HCT116 Cells; Humans; Immunohistochemistry; Mice; Mutation; Neoplasms; Positron-Emission Tomography; Thymidine; Transplantation, Heterologous | 2013 |
Impact of different standardized uptake value measures on PET-based quantification of treatment response.
Topics: Biological Transport; Dideoxynucleosides; Humans; Neoplasms; Positron-Emission Tomography; Reference Standards; Treatment Outcome | 2013 |
Interstitial diffusion and the relationship between compartment modelling and multi-scale spatial-temporal modelling of (18)F-FLT tumour uptake dynamics.
Topics: Dideoxynucleosides; Humans; Models, Biological; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2014 |
Predictive Value of Early-Stage Uptake of 3'-Deoxy-3'-18F-Fluorothymidine in Cancer Cells Treated with Charged Particle Irradiation.
Topics: Animals; Carbon; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Dose-Response Relationship, Radiation; Ions; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Particle Size; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Time Factors; Tissue Distribution; X-Rays | 2015 |
Effects of capecitabine treatment on the uptake of thymidine analogs using exploratory PET imaging agents:
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Arabinofuranosyluracil; Capecitabine; Dideoxynucleosides; Female; Humans; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2016 |
Topics: Adult; Aged; Aged, 80 and over; Axitinib; Dideoxynucleosides; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A | 2016 |
Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine.
Topics: Animals; Cell Proliferation; Clinical Trials as Topic; Diagnosis, Differential; Dideoxynucleosides; Disease Models, Animal; Fluorodeoxyglucose F18; Humans; Molecular Diagnostic Techniques; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2009 |
Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats.
Topics: Animals; Diagnosis, Differential; Dideoxynucleosides; Feasibility Studies; Female; Fluorodeoxyglucose F18; Inflammation; Neoplasms; Positron-Emission Tomography; Rats; Thymidine Phosphorylase; Tissue Distribution; Tyrosine | 2009 |
The integration of quantitative multi-modality imaging data into mathematical models of tumors.
Topics: Annexin A5; Apoptosis; Cell Hypoxia; Cell Movement; Cell Proliferation; Diagnostic Imaging; Dideoxynucleosides; Diffusion; Logistic Models; Magnetic Resonance Imaging; Models, Biological; Neoplasms; Organotechnetium Compounds; Positron-Emission Tomography; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2010 |
Increase of [(18)F]FLT tumor uptake in vivo mediated by FdUrd: toward improving cell proliferation positron emission tomography.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Flow Cytometry; Floxuridine; Humans; Magnetic Resonance Imaging; Mice; Neoplasms; Positron-Emission Tomography; Time Factors; Tissue Distribution; Xenograft Model Antitumor Assays | 2011 |
Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model.
Topics: Animals; Biological Transport; Cell Line, Tumor; Cell Transformation, Neoplastic; Dideoxynucleosides; Equilibrative Nucleoside Transporter 1; Female; Gene Knockdown Techniques; Gene Knockout Techniques; Humans; Mice; Mice, Knockout; Neoplasms; Positron-Emission Tomography; RNA, Messenger; RNA, Small Interfering; Spleen; Thioinosine; Thymidine; Thymidine Kinase; Transfection | 2010 |
Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells.
Topics: Arabinofuranosyluracil; Biological Transport; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Equilibrative Nucleoside Transport Proteins; Humans; Kinetics; Neoplasms; Positron-Emission Tomography; Thymidine; Tritium | 2010 |
Can evaluation of targeted therapy in oncology be improved by means of 18F-FLT?
Topics: Dideoxynucleosides; Drug Delivery Systems; Humans; Image Enhancement; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2010 |
Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dideoxynucleosides; Drug Synergism; Female; Fluorine Radioisotopes; Fluorouracil; Humans; Indium Radioisotopes; Leucovorin; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Positron-Emission Tomography; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Humans; Male; Mice; Mitosis; Neoplasms; Positron-Emission Tomography; Protein Multimerization; Protein Structure, Quaternary; Thymidine Kinase; Time Factors; Tubulin; Tubulin Modulators; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
SNM clinical trials network validates 100th scanner.
Topics: Clinical Trials as Topic; Dideoxynucleosides; Humans; Medical Oncology; Multicenter Studies as Topic; Neoplasms; Nuclear Medicine; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed | 2011 |
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.
Topics: Animals; Aurora Kinase A; Aurora Kinases; Azepines; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Female; Fluorine Radioisotopes; HCT116 Cells; HeLa Cells; Humans; Lymphoma; Mice; Mice, Nude; Mice, SCID; Mitotic Index; Molecular Structure; Neoplasms; Phosphorylation; Positron-Emission Tomography; Protein Serine-Threonine Kinases; Pyrimidines; Spindle Apparatus; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
[(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Cell Cycle Checkpoints; Cell Proliferation; Cyclin-Dependent Kinases; Dideoxynucleosides; Disease Models, Animal; Humans; Mice; Mice, Nude; Mice, SCID; Neoplasms; Piperazines; Positron-Emission Tomography; Pyridines; Thymidine; Xenograft Model Antitumor Assays | 2012 |
PET imaging of tumor growth: not as easy as it looks.
Topics: Animals; Dideoxynucleosides; Humans; Neoplasms; Positron-Emission Tomography | 2012 |
Double-input compartmental modeling and spectral analysis for the quantification of positron emission tomography data in oncology.
Topics: Dideoxynucleosides; Fluorouracil; Humans; Kinetics; Models, Biological; Neoplasms; Positron-Emission Tomography; Radioactive Tracers; Spectrum Analysis; Statistics as Topic | 2012 |
3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Topics: Adenosine Triphosphate; Animals; Dideoxynucleosides; Drug Monitoring; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Humans; Mice; Mice, Inbred C3H; Mice, Nude; Neoplasms; Neoplasms, Experimental; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Transplantation, Heterologous | 2003 |
PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls.
Topics: Animals; Dideoxynucleosides; Fluorine Radioisotopes; Humans; Neoplasm Staging; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Thymidine | 2003 |
Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs.
Topics: Animals; Arabinofuranosyluracil; Cell Division; Cell Line, Tumor; Dideoxynucleosides; DNA; Drug Delivery Systems; Humans; Metabolic Clearance Rate; Mice; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Thymidine; Thymidine Kinase; Tomography, Emission-Computed; Tritium | 2003 |
Correspondence re: H. Barthel et al., 3'-deoxy-3'-[(18)F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res., 63: 3791-3798, 2003.
Topics: Dideoxynucleosides; Drug Monitoring; Humans; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies.
Topics: Algorithms; Cell Proliferation; Computer Simulation; Dideoxynucleosides; Image Interpretation, Computer-Assisted; Kinetics; Metabolic Clearance Rate; Models, Biological; Neoplasm Staging; Neoplasms; Radioisotope Dilution Technique; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution | 2005 |
Molecular imaging in animal models of disease--every little detail counts!
Topics: Animals; Artifacts; Dideoxynucleosides; Dogs; Humans; Mice; Molecular Probe Techniques; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Rats; Reproducibility of Results; Sensitivity and Specificity; Species Specificity; Tissue Distribution | 2005 |
Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose?
Topics: Animals; Antineoplastic Agents; Dideoxynucleosides; Disease Models, Animal; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Mice; Neoplasms; Radionuclide Imaging; Reproducibility of Results | 2006 |
Simple and highly efficient synthesis of 3'-deoxy-3'-[18F]fluorothymidine using nucleophilic fluorination catalyzed by protic solvent.
Topics: Automation; Cell Proliferation; Chromatography, Thin Layer; Dideoxynucleosides; Fluorine Radioisotopes; Halogenation; Humans; Neoplasms; Quality Control; Radiochemistry; Radiopharmaceuticals; Solvents; Temperature; Time Factors | 2007 |
Assessment of therapy response in malignant tumours with 18F-fluorothymidine.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dideoxynucleosides; Humans; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Evaluation of 5'-deoxy-5'-[F-18]fluorothymidine as a tracer of intracellular thymidine phosphorylase activity.
Topics: Cell Line, Tumor; Dideoxynucleosides; Enzyme Activation; Humans; Metabolic Clearance Rate; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Thymidine Phosphorylase; U937 Cells | 2007 |
The role of 18F-FLT in cancer imaging: does it really reflect proliferation?
Topics: Animals; Cell Proliferation; Dideoxynucleosides; Humans; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals | 2008 |